Cyclic Ruthenium-Peptide Conjugates as Integrin-Targeting Phototherapeutic Prodrugs for the Treatment of Brain Tumors
Journal of the American Chemical Society · 2023
DOI: 10.1021/jacs.3c04855 ↗At a glance
Journal article in Journal of the American Chemical Society, 2023. Written by Liyan Zhang and 12 co-authors. Institution: Leiden Institute of Chemistry, Universiteit Leiden, Einsteinweg 55, 2333 CC Leiden, Netherlands. Major MEDLINE topics: Ruthenium, Prodrugs, Brain Neoplasms, Coordination Complexes. Cited 94 times so far (Crossref); 72 references. The full text is freely available (open access, CC BY 4.0). Funded by: European Research Council, China Scholarship Council, National Natural Science Foundation of China.
Abstract (original language)
To investigate the potential of tumor-targeting photoactivated chemotherapy, a chiral ruthenium-based anticancer warhead, Λ/Δ-[Ru(Ph2phen)2(OH2)2]2+, was conjugated to the RGD-containing Ac-MRGDH-NH2 peptide by direct coordination of the M and H residues to the metal. This design afforded two diastereoisomers of a cyclic metallopeptide, Λ-[1]Cl2 and Δ-[1]Cl2. In the dark, the ruthenium-chelating peptide had a triple action. First, it prevented other biomolecules from coordinating with the metal center. Second, its hydrophilicity made [1]Cl2 amphiphilic so that it self-assembled in culture medium into nanoparticles. Third, it acted as a tumor-targeting motif by strongly binding to the integrin (Kd = 0.061 μM for the binding of Λ-[1]Cl2 to αIIbβ3), which resulted in the receptor-mediated uptake of the conjugate in vitro. Phototoxicity studies in two-dimensional (2D) monolayers of A549, U87MG, and PC-3 human cancer cell lines and U87MG three-dimensional (3D) tumor spheroids showed that the two isomers of [1]Cl2 were strongly phototoxic, with photoindexes up to 17. Mechanistic studies indicated that such phototoxicity was due to a combination of photodynamic therapy (PDT) and photoactivated chemotherapy (PACT) effects, resulting from both reactive oxygen species generation and peptide photosubstitution. Finally, in vivo studies in a subcutaneous U87MG glioblastoma mice model showed that [1]Cl2 efficiently accumulated in the tumor 12 h after injection, where green light irradiation generated a stronger tumoricidal effect than a nontargeted analogue ruthenium complex [2]Cl2. Considering the absence of systemic toxicity for the treated mice, these results demonstrate the high potential of light-sensitive integrin-targeted ruthenium-based anticancer compounds for the treatment of brain cancer in vivo.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Leiden Institute of Chemistry, Universiteit Leiden, Einsteinweg 55, 2333 CC Leiden, Netherlands.
- State Key Laboratory of Fine Chemicals, Dalian University of Technology, 2 Linggong Road, Dalian 116024, P. R. China.
- Key Laboratory of Design and Assembly of Functional Nanostructures, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, Fuzhou 350002, P. R. China.
- Leiden Institute of Biology, Universiteit Leiden, Einsteinweg 55, 2333 CC Leiden, Netherlands.
- Leiden Academic Centre for Drug Research, Universiteit Leiden, Einsteinweg 55, 2333 CC Leiden, Netherlands.
- Department of Chemistry and Industrial Chemistry, University of Pisa, 56124 Pisa, Italy.
ORCID profiles: Peiyuan Wang, Ludovic Bretin, Yurii Husiev, Tarita Biver, Sylvia E Le Dévédec, Wen Sun, Sylvestre Bonnet
Funding
- European Research Council
- China Scholarship Council
- National Natural Science Foundation of China
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Cite
APA
Zhang, L., Wang, P., Zhou, X. Q., Bretin, L., Zeng, X., Husiev, Y., Polanco, E. A., Zhao, G., Wijaya, L. S., Biver, T., Le Dévédec, S. E., Sun, W., & Bonnet, S. (2023). Cyclic Ruthenium-Peptide Conjugates as Integrin-Targeting Phototherapeutic Prodrugs for the Treatment of Brain Tumors. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.3c04855
Vancouver
Zhang L, Wang P, Zhou XQ, Bretin L, Zeng X, Husiev Y, et al. Cyclic Ruthenium-Peptide Conjugates as Integrin-Targeting Phototherapeutic Prodrugs for the Treatment of Brain Tumors. Journal of the American Chemical Society. 2023. doi:10.1021/jacs.3c04855
BibTeX
@article{Zhang2023,
author = {Zhang, Liyan and Wang, Peiyuan and Zhou, Xue-Quan and Bretin, Ludovic and Zeng, Xiaolong and Husiev, Yurii and Polanco, Ehider A and Zhao, Gangyin and Wijaya, Lukas S and Biver, Tarita and Le Dévédec, Sylvia E and Sun, Wen and Bonnet, Sylvestre},
title = {Cyclic Ruthenium-Peptide Conjugates as Integrin-Targeting Phototherapeutic Prodrugs for the Treatment of Brain Tumors},
journal = {Journal of the American Chemical Society},
year = {2023},
doi = {10.1021/jacs.3c04855}
}
EUVIMED